[
    {
        "title": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.",
        "paper_uid": "5fc10a78",
        "reference": "Burmester GR. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases. 2016;75(6):1081.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "paper_uid": "1fbf0f4e",
        "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "save_folder_path": null,
        "study_design": "SYSTEMATIC_REVIEW"
    },
    {
        "title": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.",
        "paper_uid": "f1b7a867",
        "reference": "Geng Z. Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. [Review]. Clinical & Experimental Rheumatology.2018 Aug 29.",
        "save_folder_path": null,
        "study_design": "SYSTEMATIC_REVIEW"
    }
]